CombinAble.AI
Category: AI in Biotech / Drug Discovery
AI-driven biotech company using physics-informed machine learning and molecular simulation to design and optimize therapeutic antibodies in silico. CombinAble.AI was founded in 2023. The company is led by Daria Kokh, PhD. Based in Rehovot, Israel. Latest round: Acquired. Key investors include AION Labs (venture studio backed by Pfizer, AstraZeneca, Merck KGaA, Teva, AWS, Israel Biotech Fund, Amiti Ventures, Israel Innovation Authority).
- Founded
- 2023
- Headquarters
- Rehovot, Israel
Value proposition
Replaces traditional trial-and-error antibody discovery with a single in-silico, multi-parameter optimization platform, shortening development timelines and improving developability of drug candidates.
Products and solutions
In silico antibody design and optimization platform, physics-informed AI engine pre-trained on 100,000+ molecular dynamics surrogates to predict protein structure/flexibility, now integrated into insitro's TherML platform for multi-specific antibodies and T-cell engagers.
Unique value
Physics-informed AI modeling that jointly optimizes potency, selectivity, stability and manufacturability for complex biologics (antibodies), rather than optimizing sequentially.
Target customer
Global pharmaceutical companies and biotech drug developers (via AION Labs pharma coalition, now insitro's internal R&D pipeline)
Industries served
Biotechnology, Pharmaceutical R&D, Drug Discovery
Technology advantage
Proprietary physics-informed, AI-driven optimization engine combining machine learning with computational molecular dynamics simulation, specialized for complex biologics/antibody design.
How they differentiate
Focus on physics-informed AI modeling specifically for complex biologics (antibodies, multi-specifics, T-cell engagers) rather than general protein or small-molecule design; deep integration with molecular dynamics simulation.
Main competitors
Nabla Bio, Absci, Chai Discovery, Latent Labs (AI-driven antibody/protein design platforms)
Key partnerships
Incubated within AION Labs venture studio, founded by Merck KGaA, AstraZeneca, Pfizer, Teva, Amazon Web Services (AWS), and Israel Biotech Fund, with strategic partner Amiti Ventures and support from the Israel Innovation Authority, post-acquisition integrated into insitro (Daphne Koller, CEO).
Major milestones
Founded 2023 within AION Labs, launched publicly March 2024 (AION Labs' 5th startup), acquired by insitro, announced January 12, 2026 (deal expected to close late January 2026), becoming insitro's new Israel R&D center for large-molecule design and launch base for insitro's TherML platform.
Market positioning
Niche deep-tech player in AI-driven antibody/biologics design, incubated by a pharma-industry-backed venture studio, now the biologics arm of insitro's full-stack modality-agnostic drug design platform (TherML).
Geographic focus
Global (Israel R&D hub within a US-headquartered AI therapeutics company post-acquisition)
About Daria Kokh, PhD
Co-founder & CEO of CombinAbleAI since founding (2023); PhD-level computational biology/molecular simulation background; incubated venture within AION Labs venture studio (Rehovot, Israel).
Latest news about CombinAble.AI
More AI in Biotech / Drug Discovery companies
Official website: https://www.combinable.ai